Providing a Holistic View of Vector Testing and Characterization for Manufacturing of Genetically Modified T-Cells

Time: 11:00 am
day: Day 2 Track B


  • Leveraging molecular tools for vector characterization
  • Determining optimal vector dose with the goal to balance potential safety risks and anti-tumor activity
  • Planning batch comparability and scale-up for late-stage development